Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.39 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2509746 | 1.00 | TLR9 (0.42) | TLR9EPHX1SLC5A2SLC6A2SLC6A4 | |
| SCHEMBL31231840 | 0.80 | TLR9 (0.47) | TLR9SLC6A2SLC6A4SLC6A3CTRB1 | |
| SCHEMBL24989060 | 0.79 | TSHR (0.48) | SLC5A2 | |
| SCHEMBL11825236 | 0.78 | FASN (0.47) | SLC5A2SLC6A2SLC6A4SLC6A3FASN | |
| SCHEMBL30450943 | 0.78 | MAPT (0.42) | SLC5A2LMNASMN1; SMN2 | |
| SCHEMBL21284279 | 0.76 | EPHX1 (0.34) | EPHX1SLC5A2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3260343 | 0.74 | SLC5A2 (0.50) | EPHX1SLC5A2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9475300 | 0.74 | SLC5A2 (0.50) | EPHX1SLC5A2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11277296 | 0.74 | TLR9 (0.43) | TLR9SLC6A2SLC6A4SLC6A3CTRB1 | |
| SCHEMBL9486645 | 0.74 | SLC5A2 (0.50) | EPHX1SLC5A2CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815951-B2 | Inhibitors of epoxide hydrolases for the treatment of inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-06 | — | — | US | disclosed |
| US-20080188554-A1 | METHODS OF TREATING AVIAN HYPERTENSION | REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188554-A1 | METHODS OF TREATING AVIAN HYPERTENSION | REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2008-08-07 | — | — | US | disclosed |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-24 | — | — | US | disclosed |
| US-20050282767-A1 | Inhibitors of epoxide hydrolases for the treatment of hypertension | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, OFFICE OF TECHNOLOGY TRANSFER (US) | 2005-12-22 | — | — | US | disclosed |
| US-6756210-B2 | DETECTING PRE-ECLAMPSIA, AND PREGNANCY-INDUCED HYPERTENSION BY WAY OF ABNORMAL REGULATION OF CYTOCHROME P450 METABOLISM; ENZYME INHIBITORS; OXIDOREDUCTASES; EPOXIDE HYDROLASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-06-29 | — | — | US | disclosed |
| US-20040092487-A1 | Inhibitors of epoxide hydrolases for the treatment of hypertension | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-05-13 | — | — | US | disclosed |
| US-6693130-B2 | UREAS, AMIDES, AND CARBAMATES; DICYCLOHEXYL UREA | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-02-17 | — | — | US | disclosed |
| US-20030119900-A1 | Inhibitors of epoxide hydrolases for the treatment of hypertension | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-06-26 | — | — | US | disclosed |
| US-20030113824-A1 | Dihydroxy unsaturated fatty acid levels as diagnostic markers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-06-19 | — | — | US | disclosed |
| EP-0724569-B1 | PROCESS FOR THE PREPARATION OF AN OXIRANE, AZIRIDINE OR CYCLOPROPANE | AVECIA LTD (GB) | 2003-03-12 | — | — | EP | disclosed |
| US-6531506-B1 | Inhibitors of epoxide hydrolases for the treatment of hypertension | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-03-11 | — | — | US | disclosed |
| US-5703246-A | REACTING AN ORGANOMETALLIC COMPOUND WITH ORGANOSULFUR COMPOUND | ZENECA LIMITED (GB) | 1997-12-30 | — | — | US | disclosed |
| EP-0724569-A1 | PROCESS FOR THE PREPARATION OF AN OXIRANE, AZIRIDINE OR CYCLOPROPANE | ZENECA LIMITED (GB) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995011230-A1 | PROCESS FOR THE PREPARATION OF AN OXIRANE, AZIRIDINE OR CYCLOPROPANE | ZENECA LIMITED (GB) | 1995-04-27 | — | — | WO | disclosed |
| US-4186255-A | POLYURETHANE CATALYST | TEXACO DEVELOPMENT CORPORATION (US) | 1980-01-29 | — | — | US | disclosed |
| US-4136240-A | METALLIC QUATERNARY AMMONIUM CARBOXYLATES AS POLYISOCYANURATE CATALYSTS | TEXACO DEVELOPMENT CORPORATION (US) | 1979-01-23 | — | — | US | disclosed |
| US-4075130-A | DIAMINES, TRIAMINES | TEXACO DEVELOPMENT CORPORATION (US) | 1978-02-21 | — | — | US | disclosed |
| US-4060501-A | Novolak derivatives as defoamers | TEXACO DEVELOPMENT CORPORATION (US) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | EPHX1, EPHX2, NCEH1 | TLR9 4557/4885EPHX1 1/4885SLC5A2 2501/4885 |
| US-20030119900-A1 | Inhibitors of epoxide hydrolases for the treatment of hypertension | EPHX1, NCEH1, EPHX2 | TLR9 4524/4885EPHX1 1/4885SLC5A2 2588/4885 |
| US-20080188554-A1 | METHODS OF TREATING AVIAN HYPERTENSION | EPHX1, ERH, EPHX2 | TLR9 1821/4885EPHX1 1/4885SLC5A2 2146/4885 |
| US-20030113824-A1 | Dihydroxy unsaturated fatty acid levels as diagnostic markers | ALOX12, ALOX15, ALOX5 | TLR9 3782/4885EPHX1 15/4885SLC5A2 2629/4885 |
| US-20040092487-A1 | Inhibitors of epoxide hydrolases for the treatment of hypertension | EPHX1, NCEH1, EPHX2 | TLR9 4524/4885EPHX1 1/4885SLC5A2 2588/4885 |
| US-20050282767-A1 | Inhibitors of epoxide hydrolases for the treatment of hypertension | EPHX1, EPHX2, NCEH1 | TLR9 4571/4885EPHX1 1/4885SLC5A2 2477/4885 |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | EPHX1, LTA4H, PTGS1 | TLR9 2252/4885EPHX1 1/4885SLC5A2 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.